Unique openings in specific ion channels could lead to development of selective drugs

Gilead Sci­ences is fo­cus­ing on the over­looked needs of peo­ple liv­ing with metasta­t­ic and triple-neg­a­tive breast can­cer in its lat­est un­brand­ed on­col­o­gy cam­paign. The “Ex­pose

Fu­sion Phar­ma­ceu­ti­cals said it has man­u­fac­tured the first clin­i­cal dose of its ra­dio­phar­ma­ceu­ti­cal as­set in-house and has agreed with the FDA on the de­sign of